[1] RAJKUMAR S V,KYLE R A.Multiple myeloma:diagnosis and treatment[J].Mayo Clin Proc,2005,80(10):1371-1382.
[2] NIJHOF I S,VAN DE DONK N W C J,ZWEEGMAN S,et al.Current and new therapeutic strategies for relapsed and refractory multiple myeloma:an update[J].Drugs,2018,78(1):19-37.
[3] PALUMBO A,CHANAN-KHAN A,WEISEL K,et al.Daratumumab,bortezomib,and dexamethasone for multiple myeloma[J].N Engl J Med,2016,375(8):754-766.
[4] CHARI A,SUVANNASANKHA A,FAY J W,et al.Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma[J].Blood,2017,130(8):974-981.
[5] LANCMAN G,ARINSBURG S,JHANG J,et al.Blood transfusion management for patients treated with anti-CD38 monoclonal antibodies[J].Front Immunol,2018,9:2616.
[6] CHAPUY C I,NICHOLSON R T,AGUAD M D,et al.Resolving the daratumumab interference with blood compatibility testing[J].Transfusion,2015,55(6pt2):1545-1554.
[7] OOSTENDORP M,LAMMERTS VAN BUEREN J J,DOSHI P,et al.When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy[J].Transfusion,2015,55(6pt2):1555-1562.
[8] MALAVASI F,FUNARO A,ROGGERO S,et al.Human CD38:a glycoprotein in search of a function[J].Immunol Today,1994,15(3):95-97.
[9] LIN P,OWENS R,TRICOT G,et al.Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma[J].Am J Clin Pathol,2004,121(4):482-488.
[10] REINHERZ E L,KUNG P C,GOLDSTEIN G,et al.Discrete stages of human intrathymic differentiation:Analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage[J].PNAS,1980,77(3):1588-1592.
[11] TERHORST C,VAN AGTHOVEN A,LECLAIR K,et al.Biochemical studies of the human thymocyte cell-surface antigens T6,T9 and T10[J].Cell,1981,23(3):771-780.
[12] MEHTA K,SHAHID U,MALAVASI F.Human CD38,a cell-surface protein with multiple functions[J].FASEB J,1996,10(12):1408-1417.
[13] CROWELL P D,GOLDSTEIN A S.Functional evidence that progenitor cells near sites of inflammation are precursors for aggressive prostate cancer[J].Mol Cell Oncol,2017,4(2):e1279723.
[14] KOTLIKOFF M I,KANNAN M S,SOLWAY J,et al.Methodologic advancements in the study of airway smooth muscle[J].J Allergy Clin Immunol,2004,114(2):S18-S31.
[15] HORENSTEIN A L,SIZZANO F,LUSSO R,et al.CD38 and CD157 ectoenzymes mark cell subsets in the human corneal limbus[J].Mol Med,2009,15(3/4):76-84.
[16] DEAGLIO S,MEHTA K,MALAVASI F.Human CD38:a (r)evolutionary story of enzymes and receptors[J].Leuk Res,2001,25(1):1-12.
[17] DECKERT J,WETZEL M C,BARTLE L M,et al.SAR650984,A novel humanized CD38-targeting antibody,demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies[J].Clin Cancer Res,2014,20(17):4574-4583.
[18] OVERDIJK M B,JANSEN J H M,NEDEREND M,et al.The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via fcγreceptor-mediated cross-linking[J].J Immunol,2016,197(3):807-813.
[19] JIANG H,ACHARYA C,AN G,et al.SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways,which is further enhanced by pomalidomide[J].Leukemia,2016,30(2):399-408.
[20] BONELLO F,D’AGOSTINO M,MOSCVIN M,et al.CD38 as an immunotherapeutic target in multiple myeloma[J].Expert Opin Biol Ther,2018,18(12):1209-1221.
[21] VAN BUEREN J L,JAKOBS D,KALDENHOVEN N,et al.Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087,SAR650984 and Ab79[J].Blood,2014,124(21):3474.
[22] WANG X,DAHL M,NGUYEN D,et al.The Anti-CD38 Monoclonal Antibody TAK-079 Depletes Antibody Secreting Cells from Normal and SLE Patients[J].Arthritis Rheumatol,2016,68(S10):1085.
[23] GOLDMACHER V S,BOURRET L A,LEVINE B A,et al.Anti-CD38-blocked ricin:an immunotoxin for the treatment of multiple myeloma[J].Blood,1994,84(9):3017-3025.
[24] A BOLOGNESI,L POLITO,V FARINI,et al.CD38 as a target of IB4 mAb carrying saporin-S6:design of an immunotoxin for ex vivo depletion of hematological CD38+ neoplasia[J].J Biol Regul Homeost Agents,2005,19(3-4):145-152.
[25] RICHTER J R,LANDGREN C O,KAUH J S,et al.Phase 1,multicenter,open-label study of single-agent bispecific antibody t-cell engager GBR1342 in relapsed/refractory multiple myeloma[J].J Clin Oncol,2018,36(15_suppl):TPS3132.
[26] KREJCIK J,CASNEUF T,NIJHOF I S,et al.Daratumumab depletes CD38+ immune regulatory cells,promotes T-cell expansion,and skews T-cell repertoire in multiple myeloma[J].Blood,2016,128(3):384-394.
[27] DE WEERS M,TAI Y T,VAN DER VEER M S,et al.Daratumumab,a novel therapeutic human CD38 monoclonal antibody,induces killing of multiple myeloma and other hematological tumors[J].J Immunol,2011,186(3):1840-1848.
[28] LINTEL N J,BROWN D K,SCHAFER D T,et al.Use of standard laboratory methods to obviate routine dithiothreitol treatment of blood samples with daratumumab interference[J].Immunohematology,2017,33(1):22-26.
[29] LALEZARI P,JIANG A F.The manual polybrene test:a simple and rapid procedure for detection of red cell antibodies[J].Transfusion,1980,20(2):206-211.
[30] SUN J B.The prenatal intervention of pregnancy complicated with anti-Kell isoimmunization:a review[J].J Matern - Fetal Neonatal Med,2019:1-7.
[31] LIU F P,LIU J C.Possible insensitivity of the polybrene antibody screen to detect anti-Jka[J].Annals of Clinical and Laboratory Science,2006,36(1):101-2.
[32] YEH T J,YEH C J,LIU Y C,et al.Manual polybrene method for pretransfusion test could overcome the interference of daratumumab therapy in myeloma[J].Transfusion,2019,59(8):2751-2752.
[33] DE VOOGHT K M K,OOSTENDORP M,VAN SOLINGE W W.Dealing with anti-CD38 (daratumumab) interference in blood compatibility testing[J].Transfusion,2016,56(3):778-779.
[34] QUACH H,BENSON S,HAYSOM H,et al.Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma[J].Intern Med J,2018,48(2):210-220.
[35] ANANI W Q,MARCHAN M G,BENSING K M,et al.Practical approaches and costs for provisioning safe transfusions during anti-CD38 therapy[J].Transfusion,2017,57(6):1470-1479.
[36] SCHMIDT A E,KIRKLEY S,PATEL N,et al.An alternative method to dithiothreitol treatment for antibody screening in patients receiving daratumumab[J].Transfusion,2015,55(9):2292-2293.
[37] ANANI W Q,DUFFER K,KAUFMAN R M,et al.How do I work up pretransfusion samples containing anti-CD38?[J].Transfusion,2017,57(6):1337-1342.
[38] VELLIQUETTE R,SHAKARIAN G,JHANG J,et al.Daratumumab-derived anti-CD38 can be easily mistaken for clinically significant antibodies to Lutheran antigens or to Knops antigens[J].Transfusion,2015,55(S3):26A.
[39] AYE T,ARNDT PA,LEGER RM,et al.Myeloma patients receiving daratumumab (anti-CD38) can appear to have an antibody with Lutheran-related specificity[J].Transfusion,2015,55(S3):28A.
[40] CHAPUY C I,AGUAD M D,NICHOLSON R T,et al.International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing[J].Transfusion,2016,56(12):2964-2972.
[41] HUGAN S L,COOLING L,LARSSON V M.An evaluation of storage time for dithiothreitol-treated reagent cells[J].Transfusion,2017,57(10):2545-2546.
[42] LALLY K,HAYES C,HIS R,et al.Extended Use of DTT-Treated Reagent Red Cells in the Era of anti-CD38 Therapy[J].2016,56(S4):136A.
[43] HOSOKAWA M,KASHIWAGI H,NAKAYAMA K,et al.Distinct effects of daratumumab on indirect and direct antiglobulin tests:a new method employing 0.01 mol/L dithiothreitol for negating the daratumumab interference with preserving K antigenicity (Osaka method)[J].Transfusion,2018,58(12):3003-3013.
[44] LORENZEN H,LONE AKHTAR N,NIELSEN M,et al.Thirty-three-day storage of dithiothreitol-treated red blood cells used to eliminate daratumumab interference in serological testing[J].Vox Sang,2018,113(7):686-693.
[45] REID M E,LOMAS-FRANCIS C,OLSSON M L.Introduction[M]//The Blood Group Antigen FactsBook.Amsterdam:Elsevier,2012:3-7.
[46] BUB C B,REIS I N D,ARAVECHIA M G,et al.Transfusion management for patients taking an anti-CD38 monoclonal antibody[J].Hematol Transfus Cell Ther,2018,40(1):25-29.
[47] F(ab')2 fragments to overcome daratumumab interference in transfusion tests[J].N Engl J Med,2019,380(2):202.
[48] CHINOCA ZIZA K N,PAIVA T A,MOTA S R,et al.A blockage monoclonal antibody protocol as an alternative strategy to avoid anti-CD38 interference in immunohematological testing[J].Transfusion,2019,59(5):1827-1835.
[49] VAN DE DONK N W C J,RICHARDSON P G,MALAVASI F.CD38 antibodies in multiple myeloma:back to the future[J].Blood,2018,131(1):13-29.
[50] SULLIVAN H C,GERNER-SMIDT C,NOOKA A K,et al.Daratumumab (anti-CD38) induces loss of CD38 on red blood cells[J].Blood,2017,129(22):3033-3037.
[51] CHARI A,SATTA T,TAYAL A,et al.Outcomes and management of red blood cell transfusions in multiple myeloma patients treated with daratumumab[J].Blood,2015,126(23):3571. |
